• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Finger Michael H. sold $8,062 worth of shares (1,500 units at $5.38), decreasing direct ownership by 81% to 351 units (SEC Form 4)

    2/20/25 7:23:52 PM ET
    $CELZ
    Finance: Consumer Services
    Finance
    Get the next $CELZ alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Finger Michael H.

    (Last) (First) (Middle)
    1551 N. DIANE ST.

    (Street)
    MESA AZ 85203-3850

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. [ CELZ ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/18/2025 S 750 D $5 1,101 D
    Common Stock 02/19/2025 S 750 D $5.75 351 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Michael H. Finger 02/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CELZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELZ

    DatePrice TargetRatingAnalyst
    2/25/2022$10.00Buy
    Roth Capital
    More analyst ratings

    $CELZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

    PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate

    10/29/25 9:00:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Issues Letter to Shareholders

    PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company's history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications. At the

    10/27/25 8:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

    PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel wi

    10/7/25 9:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    SEC Filings

    View All

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    8/8/25 4:45:55 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    5/9/25 4:45:24 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    5/6/25 4:30:30 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Creative Medical Tech with a new price target

    Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00

    2/25/22 9:18:39 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Finger Michael H. sold $8,062 worth of shares (1,500 units at $5.38), decreasing direct ownership by 81% to 351 units (SEC Form 4)

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    2/20/25 7:23:52 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Warbington Timothy

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    6/29/23 5:37:18 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4: Warbington Timothy bought $9,862 worth of shares (25,000 units at $0.39), increasing direct ownership by 29% to 112,087 units

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    11/23/22 9:09:14 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Leadership Updates

    Live Leadership Updates

    View All

    Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

    PHOENIX, Ariz. , March 2, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing, and business development. He most recently served

    3/2/22 8:30:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/26/23 10:23:18 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Creative Medical Technology Holdings Inc.

    SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/1/23 9:49:02 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    2/14/22 3:30:56 PM ET
    $CELZ
    Finance: Consumer Services
    Finance